Retinol
As of the edition of 20 October 2026, Retinol is a small molecule: marketed, first approved in 1958 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Small molecule
- Brand name
- Aquasol A
- First approved
- 1 February 1958 (ES)
- Approvals on record
- 24 in 5 regions
- Holder of the most recent approval
- B. Braun Medical; 12 holders in all
- Registered trials
- 43, 1 stopped early
- Disease areas
- Infections; Nutrition and metabolism; Eye; Inherited and neonatal; Lungs and airways; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 5 | 1 | 1 |
| Phase 1 | 5 | 3 | 1 | 0 |
| Phase 2 | 11 | 5 | 3 | 0 |
| Phase 3 | 8 | 7 | 0 | 0 |
| Phase 4 | 8 | 6 | 0 | 0 |
| All trials | 43 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Casper Pharma | Acquired holder | 2018 to now |
| B. Braun Medical | Applicant | 2024 to now |
| Astra | Earlier holder |